Health Care [ 8/12 ] | Pharmaceuticals [ 26/75 ]
NYSE | Common Stock
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
It operates in two segments, Innovative Medicine and MedTech.
The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand.
The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 21, 26 | 2.46 Increased by +20.59% | 2.46 |
| Oct 14, 25 | 2.80 Increased by +15.70% | 2.76 Increased by +1.45% |
| Jul 16, 25 | 2.77 Decreased by -1.77% | 2.68 Increased by +3.36% |
| Apr 15, 25 | 4.54 Increased by +67.53% | 2.26 Increased by +100.88% |
| Jan 22, 25 | 2.04 Decreased by -10.92% | 2.01 Increased by +1.49% |
| Oct 15, 24 | 2.42 Decreased by -9.02% | 2.21 Increased by +9.50% |
| Jul 17, 24 | 2.82 Increased by +0.71% | 2.70 Increased by +4.44% |
| Apr 16, 24 | 2.71 Increased by +1.12% | 2.65 Increased by +2.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 24.56 B Increased by +9.08% | 5.12 B Increased by +49.11% | Increased by +20.83% Increased by +36.70% |
| Sep 30, 25 | 23.99 B Increased by +6.77% | 5.15 B Increased by +91.24% | Increased by +21.47% Increased by +79.11% |
| Jun 30, 25 | 23.74 B Increased by +5.77% | 5.54 B Increased by +18.16% | Increased by +23.32% Increased by +11.71% |
| Mar 31, 25 | 21.89 B Increased by +2.39% | 11.00 B Increased by +237.91% | Increased by +50.24% Increased by +230.04% |
| Dec 31, 24 | 22.52 B Increased by +5.26% | 3.43 B Decreased by -15.26% | Increased by +15.24% Decreased by -19.50% |
| Sep 30, 24 | 22.47 B Increased by +5.25% | 2.69 B Decreased by -89.65% | Increased by +11.99% Decreased by -90.17% |
| Jun 30, 24 | 22.45 B Increased by +4.31% | 4.69 B Decreased by -8.90% | Increased by +20.88% Decreased by -12.67% |
| Mar 31, 24 | 21.38 B Increased by +2.34% | 3.25 B Increased by +4.89 K% | Increased by +15.22% Increased by +4.78 K% |